Multiple sclerosis (MS) is a chronic, inflammatory, progressive, demyelinating disease of the central nervous system. Treatment for MS involves long-term disease-modifying therapies (DMTs). Medication adherence in chronic diseases like MS plays an important role in predicting long-term outcomes. This is a cross-sectional, survey-based study was done to assess adherence to medications among adults suffering from MS in Medina Province, Saudi Arabia. The study sample included 90patients diagnosed with multiple sclerosis. These databases contain information about disease presentation, drug prescription, vital status, residency, and role of contact to patient. All the collected data were analyzed by an SPSS program, version 20, and p value < 0.05 was considered significant. A response rate among the MS patients was 97.78%, and their mean age was 36.13±9.58. Most of the participants were above 35 years (55%) and were females. About 37.8% of patients was considered to be adherent to the drugs. The mean total score of BMQ Specific-Necessity was 3.25±0.70 and about 63.4% total score=3 and the mean total score of BMQ Specific-Concerns was (3.34±0.703). About 84.4% total score=3. The mean total score of BMQ General was 3.2727±0.31, and about 81.1% had a total score=3. The mean total score of compliance was 3.2023±0.393.We concluded that many factors affected the patient's adherence to the drug rather than of being dependence to the drugs as worrying about side effects and the cost of the drug.
INTRODUCTION
Multiple sclerosis (MS) is one of the chronic demyelinating diseases of the central nervous system which is inflammatory and progressive. It affects mostly young adults and had higher incidence rates in females and Caucasians 1 . The first symptoms of the disease typically appear in young adults between 20 and 40 years of age which was presented mainly with visual disturbances and difficulties in movement. Due to the physical consequences of the disease, it is one of the main causes of disability among young adults and its management is a serious challenge for healthcare systems 2 . MS has been widely documented in Canada and the United Status 3 . Howeverdata about MS in the Arab world is still not clear and insufficient. In the Arabian Gulf countries, variation in MS prevalence rates have been reported with the highest prevalence rates in Kuwait (85.0/100,000), intermediate rates in the Qatari population (64.6/100,000), and low prevalence rate in Dubai of the United Arab Emirates (54.8/100,000) 4 . Treatment for MS involves longterm disease-modifying therapies (DMTs) aimed at reducing the severity of symptoms. DMT constitute the current firstline treatment option for relapsing-remitting and secondary progressive MS because they reduce the relapse rate and slow down disability progression 5 .The World Health Organization (WHO) (2003) defines adherence to treatment as the extent to which a person's behavior in taking medication, following a diet, and/or executing lifestyle changes corresponds to recommendations from a health care provider . 6. Medication adherence in chronic diseases like MS plays an important role in predicting the long-term outcomes of the patients. However, research has shown that long-term adherence to DMT represents a significant challenge for patients with MS 7 . Barriers to treatment adherence in MS patients include the chronic nature of MS, fear of injection and adverse events, perceived lack of efficacy, treatment fatigue, drug type, and health system factors [4] [5] [6] [7] [8] . Non-adherence behavior is not only costly in terms of time, money, and resources; it can also threaten the relation between doctor and patient. 5&9 However, in order to achieve the intended therapeutic effect, the patient must follow the treatment recommendationssuch as taking the drug according to the prescribed dosage for the duration of the treatment. WHO indicates that only half of the patients suffering from chronic diseases adhere to treatment recommendations. 10 Recent studies on MS patients have shown that the percentage of people who strictly adhere to treatment recommendations ranged from 49% to 93% 4 . However, previous studies have indicated that a level of adherence above 80% can be considered optimal as the adherence at this level has a significant effect in reducing the risk of hospitalization, acute medical visits and total expenditures for the management of MS patients 11 . In this study, we tried to assess adherence to medication among adults suffering from MS in Medina province, Saudi Arabia.
PATIENTS AND METHODS

Type of study
This is a cross-sectional survey-based study. Conducted over a period of two years from 2016 to 2018.
Research locale
Study population
The 
Data collection
Upon receiving ethical committee approval and informed consent patients previously diagnosed with MS were contacted to participate in a survey after completing the questionnaire. The questionnaire used included independent and dependent variables. Independent variables were socioeconomic characteristics (marital status, education, and employment state) and personal characteristics (gender and age). The dependent variables:
1) The first dependent variable was the adherence to treatment with drugs used to treat MS assessed by the Morisky Medication Adherence Scale (MMAS-8) (Morisky et al.) 13 Use of medication referred to forgetting to take the medication, stopping the medication on his or/her own when feeling better; stopping medication when feeling worse and problems related to the complexity of the therapy, the four questions are expected to be answered negatively. The degree of adherence to the treatment was determined by the scoring of the sum of all correct answers. Patients who scored 4 in the MMAS-8 were considered adherent.
2) The second dependent variable dealt with beliefs about medicines (BMQ) 14 for MS and comprised two sections: the BMQ-Specific, which assessed representations of medication prescribed for personal use, and BMQ-General, which assessed beliefs about medicines in general. The BMQ-Specific section comprised two 5item factors assessing beliefs about the necessity of prescribed medication (Specific-Necessity) and concerns about prescribed medication based on beliefs about the danger of dependence, long-term toxicity, and the disruptive effects of medication (Specific-Concerns).The BMQ-General section comprises two 3-item factors assessing medicines that are overused by doctors (General-Overuse), assessing beliefs that medicines are harmful, addictive and poisonous and should not be taken continuously (General-Harm), and assessing beliefs that medicines help people live better, longer and outweigh risks(General-Benefit scale).BMQ items were scored on a Likert-type scale: (score 1: strongly disagree, score 2: disagree, score 3: uncertain, score 4: agree, score 5: strongly agree), keeping in mind the reverse answers. A h4tim@live.com* ijlpr 2020; doi 10.22376/ijpbs/lpr.2020.10.1.L 33-42 Neurology L-35 mean item score was then calculated as the sum of each item score divided by the number of items (e.g., mean score of Specific-Necessity=(N1+N2+N3+N4+N5)/5). The Cronbach'sαs indicated that all scale measures were internally consistent in the study sample (15) with high values of αpsm=0.85, αconcern=0.75, and αnecessity=0.64, and low values of αoveruse=0.54, αharm=0.55, and αbenefit=0.58.
3) The third dependent variable: a Likert-type scale was used in the scoring of items about drug compliance in the BMQ. A pilot study was carried out (10% of the sample size (9subjects)) to evaluate the validity and reliability of the questionnaire given to participants to assess whether the Arabic version of the MARS, BMQ would be easily understood by Saudi patients. Feedback was wholly positive; however, some patients were likely to be elderly. Therefore, we provided help to patients who had any difficulty completing the questionnaire. The results of the pilot phase were not used in the final data analysis. Validation of the questionnaire was made as follows: the questionnaires were translated using a backtranslation technique. An expert translated the original questionnaire from English into Arabic. The Arabic version of the questionnaires was translated back into English by a bilingual individual. The back-translated and original versions of the questionnaire were compared with attention given to meaning and grammar.
Ethical considerations
Ethical approval for the study was obtained from the ethical review committee of the King Fahad Hospital (300/275). The nature of the study was fully explained to the study participants and consent was obtained from them. All participants were allowed to respond at their convenience and available time and their privacy was secured.
STATISTICAL ANALYSIS
The collected data were coded, entered, presented and analyzed using a data base software program, Statistical Package for Social Science (version 20, SPSS Inc, Chicago, IL).Quantitative variables were expressed as the mean ± standard deviation (SD) while the qualitative variables were expressed as a number and percentage. The results were considered statistically significant when the significant probability (P value < 0.05*).
RESULT
Regarding MMAS results which measured the patients' adherence to the drugs used for MS, about 71.1% of them forgot to take medicine, as the majority (82.2%) had problems remembering to take medicine. However, most of them (76.6%&60%) did not stop the drug when they felt well or felt worse (table 2-1). The total score of MMAS found with mean±SD was (2.0167±0.98), and about 37.8% had a total score≥3, which is considered to be adherent to the drugs ( showed that the majority of patients believed that t doctors use too many drugs and they rely onmedicines, while the General harm scale results showed that most of the patients (24.4%&60%) believed in natural remedies more than drugs, However at the same time, the majority of them did not believe in addiction of these drugs. On the other hand, about (61.1%&84.4%) confirmed that medicine helps them to live better and live longer. The total score of BMQ General with a mean±SD (3.2727±0.310) and about 81.1% had a total score≥3 (table 3-1 and graph 1). Regarding patients' compliance toward use of medicine, nearly 40% of them worried about the cost of the drugs, and half of them said that taking other drugs affected their adherence to medicine and side effects of the drug ( forgetfulness, as reported by Devonshire et al. 21 These results agreed with Castello et al. 22 who reported that barriers to maintaining treatment adherence in patients with MS include forgetting the medication, injection anxiety, perceived lack of efficacy, and coping with adverse events.Regarding the patients' concerns about drugs, nearly half of the patients worried about being dependent on the drug, and more than half of them found that medication was a mystery to them. The majority of patients believed that doctors use too many drugs.As per the current study,about (61.1% &84.4%) confirmed that medicine helps them to live better and live longer. These results agreed with the study of Camera and Gondim 17 as they reported that (77.1%) of participants were intrinsically motivated to adhere to the treatment believing that immune-modulator medication avoids the disease progression (77.3%), hoping to avoid episodes (56.9%), and hoping to get better (42.1%).In the present study regarding patients' compliance towards medicine, half of the patients said that taking other drugs and side effects of the drug affected their adherence to medicine. In agreement with the current study were the results of Ibrahim and Deleu 4 , as the majority (51%) of participants were in the age group (31-51) years, were female (54.9%), and unemployed (58.8%). They reported that the chronic condition of MS and fear of side effects from medication were the most reported reasons for noncompliance with medication.About 40% of the current study population worried about the cost of the drugs, and these results agreed with Simacek et al. 23 study in 2018, which reported that financial problems were an important reason for noncompliance with the treatment. Also, the study of Almazrouei et al. 24 reported thatthe management of patients with MS is highly costly, and this cost can increase the economic burden and cause no adherence. But these results do not agree with the study of Ibrahim and Deleu 4 which reported that financial problems were the least reported reason (19.6%) for noncompliance with medication. There was no statistically significant difference between the demographic characteristics of patients, such as age, gender, and whether the patient was adherent or not (p value>0.05).These results agreed with an Evans et al. 25 study in 2016, which reported that age, sex, and socioeconomic status were not associated with adherence to MS treatment. But the study of Higuera et al. 26 reported that older patients and males were more adherent to drugs than younger patients and females.
CONCLUSION
We concluded that many factors affected the patient's adherence to the drug rather than of being dependence to the drugs as worrying about side effects and the cost of the drug.
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